Production Capability
Our core focus
resides in R&D
Semi-synthetic formula creation and efficacy as well as streamlining production for bulk API’s.
As we continue to innovate nano-formulas from our R&D Lab, we already have 13 formulas where we have accumulated 10+ years of patient data, one formula of which is in Phase 2 (Migraine Headaches) and another which has achieved Phase 3 (ASD).
Research & Development
Rare cannabinoid discovery at GMP
Although GMP’s goal as an R&D company is to push the boundaries of rare cannabinoid discovery, we are also steadfast producers of common cannabinoids to supply the following customers:
1
Bulk API Producers of common cannabinoids (Δ8 and Δ9 THC, CBD, CBN, CBG)
2
13 formulas for the domestic and international Medical market
3
Contract Manufacturing for 3rd Parties for Nebulizer devices
4
Tissue Culture of unique cultivars to the medical and recreational market
Our R&D findings combined with our facilities capability to produce and process both our bulk material and nano-formulas is industry leading. Between our LP, NHP and DEL licensed areas, we are built to produce the cannabis medical products that will drive this industry well into the future.”Dr. Diego Delgado
Chief Medical Officer, GMP
